News 2020-04-21
Porton Successfully Receives Third US FDA Inspection.
We are proud to announce that Porton’s cGMP-compliant Erlang site located in the Chonqing Metro Region, China passed a 4-day general inspection [April 24-28, 2016] by the US FDA without any Form 483 observations. This is the third successful inspection of our China sites by the US FDA since 2013. Supported by a unified Quality Management System and Corporate Quality Group, Porton’s production sites continue to reliably deliver efficient and high-quality manufacturing solutions across the full life cycle for our valued global customers. Learn how we can help you – contact us today!
Note: Porton is still waiting for FDA’s official written document “EIR” (Establishment Investigation Report) of this Erlang inspection, more information shall be disclosed in compliance with China listed-company disclosure rules accordingly.
Note: Porton is still waiting for FDA’s official written document “EIR” (Establishment Investigation Report) of this Erlang inspection, more information shall be disclosed in compliance with China listed-company disclosure rules accordingly.
Others
More
News 2025-12-23
Porton&Nona: Strategic Partnership for Complex Antibody Therapy
Global biotech Nona partners with CDMO Porton to accelerate complex antibody drug development and commercialization.
News 2025-12-12
Porton Newsletter - November 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities Others
